Cardiology Testing April 27, 2026
Better hs-cTnT Assays, Lower Healthcare Burden April 27, 2026
Cardiac troponin assays might be the gold standard for diagnosing a heart attack in the ER, but a new JAMA study suggests the latest generation of tests could significantly reduce false positives and ultimately, health system burden.
Patient Engagement April 23, 2026
Calcium Supplements May Have CV Risks April 23, 2026
While the verdict is still out on whether or not calcium supplements support bone health, new research in JAHA suggests they’re not good for your heart.
Surgeries & Interventions April 20, 2026
A Look Into Real-World TTVR Results April 20, 2026
We’re finally starting to get some real-world data on treating tricuspid regurgitation with transcatheter tricuspid valve replacement (TTVR) and a new TVT registry study suggests TTVR outcomes are even better than previously thought.
Cardiology Business April 16, 2026
Stryker Steps into IVL with AVS Acquisition April 16, 2026
Intravascular lithotripsy is becoming a game of giants after Stryker’s announcement that it will acquire Amplitude Vascular Systems (AVS) for an undisclosed amount to add the company’s IVL system to its peripheral vascular portfolio.
Cardiology Business April 13, 2026
The Cardiologist Shortage and its Consequences April 13, 2026
We all know there’s a growing cardiologist shortage, but American cardiovascular care might hit its breaking point, with a Medicus Healthcare Solutions analysis now projecting that the shortage will only get bigger, and will hit rural communities the hardest.
Controversies April 9, 2026
Conflict of Interest Allegation Leads to Cardiologist’s Termination April 9, 2026
UPMC's structural heart president, Hemal Gada, MD, might have been terminated for whistleblowing, according to a federal lawsuit that alleges retaliatory firing following his reports of conflicts of interest regarding Edwards Lifesciences and alleged racism within UPMC.
Atrial Fibrillation April 6, 2026
CHAMPION-AF: When Noninferiority is Not Enough April 6, 2026
ACC.26 saw an overall drop in research fervor, but one long-awaited study, CHAMPION-AF, spurred a new discussion around the field of left atrial appendage closure and the data we’ve used to justify the procedure.
Cardiology April 2, 2026
The Top Trends of ACC.26 April 2, 2026
Cardiology came back to New Orleans with ACC.26 and amid the magic of “The Big Easy” some more subtle trends emerged, reflecting a maturation of cardiac science and business. Here are Cardiac Wire’s top takeaways from the conference.
Cardiology Policy March 30, 2026
A Plan to Tackle CAD Mortality by 2050 March 30, 2026
Coronary artery disease is the leading cause of cardiovascular death throughout the world, and a Lancet commission just released a new statement about what it will take to significantly reduce CAD deaths by 2050.
Cardiac Imaging March 26, 2026
What Can Fat Around the Heart Tell Us? March 26, 2026
We all know by now that too much body fat isn’t good for your heart, and new research suggests that the fat directly around your heart could play a role in your risk of coronary artery disease (CAD).
Women's Cardiac Health March 23, 2026
The CV Risks of Premature Menopause March 23, 2026
Keeping a close eye on women’s reproductive health could give insights into their future cardiovascular risk after a new JAMA study found that women who experience premature menopause face higher lifetime risk of coronary heart disease (CHD).
Population Health March 19, 2026
Ultraprocessed Foods are Bad for Everyone and Worse for Some March 19, 2026
We already know that what you put in your body is directly related to your overall health, including cardiovascular risk, but a new JACC study suggests your ethnic background could impact just how much damage ultraprocessed foods do to your body.
Population Health March 16, 2026
Where We’ve Been, and Where We’re Going in CV Health March 16, 2026
JACC released its inaugural Cardiovascular Statistics 2026 report covering a wide spectrum of major CV risk factors and conditions, and despite the medical advancements in the last ten years, it’s clear we still have a lot of work left to do.
Cardiac Imaging March 12, 2026
IVI or Angiography for Complex PCI Guidance? March 12, 2026
New follow-up data from the RENOVATE-COMPLEX-PCI trial suggests that intravascular imaging continues to provide better clinical outcomes for patients with complex coronary lesions five years after their PCI procedure.
Heart Failure March 9, 2026
Barostim Boosts QoL and LVEF, but Mortality Benefit Still Unknown March 9, 2026
Strong results from two separate studies on CVRx’s Barostim baroreflex activation therapy suggest the technology might offer symptomatic relief even though its mortality benefit is still up in the air.
Cardiology Testing March 5, 2026
What NT-proBNP Can Tell Us About TEER Outcomes March 5, 2026
New research presented at THT 2026 suggests that the NT-proBNP biomarker could give us a glimpse into which patients with severe tricuspid regurgitation (TR) will benefit the most from transcatheter edge-to-edge repair (TEER).
Cardiology Testing March 2, 2026
Two Cardiac Troponins Don’t Tell the Same Story March 2, 2026
There might be a bigger difference between the types of cardiac troponin assays, after a recent JACC analysis found that the type of troponin could help us better understand the kind of damage occurring after a heart attack.
Cardiovascular Disease February 26, 2026
Women’s CVD Will Keep Rising by 2050 February 26, 2026
Imagine an America where two out of three women suffer from cardiovascular disease. What would it look like for your mother, sister, or daughter? The American Heart Association says you won’t have to imagine for long, with its latest scientific statement painting a grim picture of women’s cardiovascular health by 2050.
Surgeries & Interventions February 23, 2026
Market Competition Drives TAVR Overutilization February 23, 2026
Whether or not a patient receives TAVR over SAVR might be more influenced by market forces than clinical evidence, after a recent study found that the more competitive the hospital market, the higher the TAVR likelihood, regardless of guideline recommendations.